Introduction
The ability of human chromosome-derived natural fragments (hCFs) as vectors for introducing large stretches of human DNA into mice was first demonstrated in 1997. 1 Transferred hCFs were stably maintained as an extra chromosome in the somatic cells of mice and the human genes included in them were expressed under proper tissue-specific regulation. In some cases they could be transmitted through the mouse germline, resulting in the establishment of novel mouse strains (trans-chromosomic (Tc) mice) containing a heritable hCF. 1, 2 Thus, such an approach employing chromosome vectors for animal transgenesis has been thought to be useful for overcoming the size constraints of cloned transgenes in conventional techniques and facilitate functional studies of human genome in the 'post sequencing' era.
Compared with conventional techniques using cloned transgenes, the chromosome vector system have several advantages: (1) whole genomic sequences including all the introns and essential regulatory elements can be used as transgenes, which results in the correct and controlled expression of transgenes in vivo; (2) very large genes, gene clusters and specific chromosomal regions, which cannot be cloned as contiguous DNA fragments by cloning techniques, can be introduced; (3) chromosome vectors are maintained as a single copy chromosome in the host cells, which may prevent artifacts and gene silencing 3 caused by multiple copy insertion of transgenes; (4) there is no risk for insertional mutagenesis because they are freely segregating from host chromosomes.
On the other hand, one major problem of hCF vectors has been that they are structurally undefined. 4, 5 The hCFs are usually generated as a consequence of accidental fragmentation of intact chromosome during the chromosome transfer process and run the risk of containing unrelated, deleterious genes in addition to the genes of interest. In this context, we recently developed a 'chromosome cloning' technique that enabled construction of human artificial chromosomes (HACs) including only defined chromosomal regions in the homologous recombination proficient chicken DT40 cell line. 6 The complete human genome sequence which is now available, 7 should facilitate the minimization of HACs containing only desired chromosomal regions.
Here, we outline the current status of our 'transchromosomic' technology and the recent progress on the development of HACs.
Results and discussion
Trans-chromosomic mice Our procedure to introduce chromosome vectors into mice is illustrated in Figure 1 . Microcell-mediated chromosome transfer (MMCT) was employed to introduce chromosome vectors into mouse embryonic stem (ES) cells. 1 Our previous studies indicated that the use of small human chromosome fragments (hCFs) may increase the probability of successful chimera production from microcell hybrid ES (MH(ES)) cells and germline transmission of the hCFs. 2 Therefore, the library comprising approximately 700 independent clones of humanmouse monochromosomal hybrids was screened to obtain small hCFs containing the gene of interest.
1,2 To date we successfully produced chimeric mice from MH(ES) cells containing the hCF derived from hChr2, 4, 6, 7, 11, 14, 21 or 22. 1, 2, 8, 9 In addition, germline transmission of transferred hCF was observed in chimeras produced from MH(ES) cells containing the hChr2, 7, 14 or 21-derived hCF.
1,2,10
Functional expression of introduced genes was extensively investigated in the Tc mice containing the transmittable hChr2-derived hCF (hCF(2-W23)) and hChr14-derived hCF (hCF(SC20)), each of which include immunoglobulin (Ig) kappa light chain (2 Mb) and heavy chain (1.5 Mb) locus, respectively.
1,2 The results of structural analysis of human Ig mRNA and Ig protein expression in the sera of Tc mice suggested that these large and complex loci were properly expressed to reconstitute the diverse and functional repertoire of human Igs in the Tc mice.
1 Furthermore, the introduction of hCF(SC20) into endogenous IgH-knockout strain, in which functional B-lymphocytes and Ig production are absent, by mating resulted in the rescue of its defects, indicating that the stability and functionality of the hCF(SC20) is likely to be sufficient for restoration of B cells in adult mice. 2 Stability tests using MH(ES) cell lines 2, 6 revealed the hCF(SC20) was highly stable (Ͻ0.1% loss/doubling) in contrast to the hCF(2-W23) (3.2% loss/doubling), hCF(22) (>5% loss/doubling) and the hChrY-derived minichromosome reported by Shen et al. 11 Similar results were obtained in various types of cell lines from different species 12 and in the somatic and germ cells of Tc mice. 2 Thus, it was suggested that each hCF may have an intrinsic level of mitotic and meiotic stability, which is less affected by the type of host cells.
Construction of HACs
This differential stability of hCFs could be another problem in using the hCFs as gene delivery vectors, in
Gene Therapy addition to the danger of including unrelated, deleterious genes as mentioned above. We therefore developed a 'chromosome-cloning' technique where a defined chromosomal region could be cloned into a stable human minichromosome vector by combination of Cre/loxPmediated chromosome translocation 13 and telomeredirected chromosome truncation 8 in homologous recombination-proficient chicken DT40 cells. 14 In our system (Figure 2 ), the hCF(SC20) was chosen as a basal minichromorome vector (SC20 vector) because of its relatively high mitotic and meiotic stability in mice. 2, 12 At first, a loxP sequence was integrated to RNR2 locus on the SC20 vector in DT40 cells, to which various chromosomal regions could be cloned. As the first model of HAC construction carrying a defined chromosomal insert, we attempted to clone the region between HCF2 and LIF loci containing Ig locus on the hChr22, the 10 Mb-sized hChr22-derived insert. In DT40 cells, the hChr22 was truncated at the LIF locus by integrating human telomeric repeats (TTAGGG)n, followed by integration of a loxP sequence to the HCF2 locus. 6 Next, the DT40 clone containing the SC20 vector and the DT40 clone containing the hChr22 fragment (hCF(22)) were fused, resulting in DT40 cell hybrids with both SC20 vector and hCF(22). The hybrids were transfected with a Cre recombinase-expression vector to induce Cre/loxPmediated chromosomal translocation between the SC20 vector and hCF(22). Occurrence of the translocation was confirmed by nested PCR analysis and then the hybrid cells containing the possible translocated chromosomal fragment were isolated by fluorescence activated cell sorter (FACS). 6 Fluorescence in situ hybridization (FISH) analysis in the sorted cells demonstrated successful generation of the human artificial chromosome (HAC) carrying the defined hChr22-derived insert, named HAC (Figure 3) .
To see the functionality of the HAC, we transferred the HAC to mouse embryonic stem (ES) cells where endogenous IgH and Ig genes were inactivated. In the ES cells, whereas hCF(22) was drastically lost after 15-day culture (about 20 doublings) under nonselective condition, HAC carrying this unstable hCF(22)-derived insert, as well as the SC20 vector itself, was stably maintained at 99.8% retention per cell division throughout the
Figure 2 Schematic diagram of the chromosome-cloning system. DT40/SC20 vector, the DT40 clone with the SC20 vector where a loxP sequence is integrated at the RNR2 locus. DT40/hCF22, the DT40 clone with the hChr22 fragment truncated at the LIF locus where a loxP sequence is integrated at the HCF2 locus. The two DT40 clones were fused, resulting in the hybrid clone containing both SC20 vector and hCF22. In the hybrid clone into which Cre recombinase was introduced, the HAC was generated by recombination between the SC20 vector and hCF22. The HAC is composed of the SC20 vector (red) and the 10 Mb-sized hChr22 insert carrying the Ig locus.

Figure 3 Verification of generation of the HAC by FISH analysis. FISH analysis of the FACS-sorted cells using hChr14 (red) and hChr22 (green)-specific probes is shown.
45-day nonselective culture (about 70 doublings) ( Figure  4 ). The fact that we could stabilize mitotically unstable hCF(22)-derived insert by cloning it into the SC20 vector suggests that the centromere of the SC20 vector dominantly contributed to mitotic stability of the HAC and that the SC20 vector may be used as a stable cloning vector for various chromosomal inserts.
To examine whether the ES cells containing the HAC have pluripotency to differentiate and whether the Ig gene on the chromosome insert of the HAC can be functionally expressed in vivo, we created chimeric mice from the MH(ES) cells using the homozygous IgH-knockout strain as a host for chimera production. In the sera of the resultant HAC chimeras, human Ig and Ig proteins were detected by enzyme linked immunosorbent assays (ELISAs) at 0.2-1 mg/ml. When immunized with human G-CSF (granulocyte colony-stimulating factor), the HAC chimera showed immune response of G-CSF-specific human Ig antibodies in the sera. These data suggest that HAC was stably maintained during development of B cells and that Ig locus on the HAC was fully functional. In addition to B cells, the HAC was also observed in tail fibroblasts of chimeras, indicating that the HAC was stably maintained in somatic cells during development in vivo.
To determine whether this chromosome-cloning system works for other hChr regions, we similarly constructed further four HACs, called #2HAC, #7HAC, ⌬HAC and ⌬⌬HAC, using the SC20 vector as a basal vector ( Figure 5 ). In the #2HAC and #7HAC, the hChr2 Gene Therapy region around Ig locus defined by yWHZ30-4 and CD8A loci (about 5 Mb) and the hChr7 region around CYP3A locus defined by COL1A2 and AF0006754 loci (about 3 Mb) were cloned into the SC20 vector, respectively. The ⌬HAC and ⌬⌬HAC carry the 2.5 Mb-sized hChr22 insert defined by HCF2 and AP000344 loci and the 1.5 Mb-sized hChr22 insert defined by AP000553 and AP000344 loci, respectively. In all the cases GFP-positive DT40 hybrid cells, in which the chromosomal insert was successfully translocated to the SC20 vector, were obtained at a frequency of 1-10 × 10 Ϫ7 per Cre transfected DT40 hybrid cells. The ⌬HAC, ⌬⌬HAC and #7HAC was introduced into mouse ES cells, respectively (see Figure 1 ) and the resultant MH(ES) cells containing each HAC were used for the production of chimeras. In the sera of ⌬HAC and ⌬⌬HAC chimeras we could detect human Ig and proteins by ELISA assays. Transcript of cytochrome P450 3A4 (CYP3A4) gene was also detected specifically in liver and small intestine of #7HAC chimeras by RT-PCR analysis, which coincides well with the tissue specificity observed in humans. Furthermore, we recently found that the ⌬HAC was germline-transmittable. Retention of the ⌬HAC was confirmed by PCR marker analysis and ELISAs for the detection of Ig and Ig . FISH analyses also revealed that the percentage of the metaphase spreads containing the ⌬HAC averaged 70% in the tail fibroblasts prepared from PCR-positive F1 offspring, which is comparable to the previous data in the Tc mice with hCF(SC20). 2 Breeding tests for the transmission of other HACs are now underway.
Potential applications
We described the chromosome-cloning system by which various hChr regions could be cloned into the SC20 minichromosome vector, irrespective of its size and introduced into mice stably, allowing human genes of interest to be functionally expressed in vivo. In our HACs, the chromosome inserts flanked by the loxP-integration and telomere-truncation sites are structurally determined by the information of the recently published human genome sequence. 7 The availability of structurally defined HAC vectors would be of great value in the construction of animals carrying human genetic elements to model specific diseases or the production of various therapeutic products for industrial purposes.
Another potential application of the HAC vector may be the use in the treatment of human genetic diseases. Indeed, the advantages of chromosome vector system in animal transgenesis, mentioned above, are also desirable characteristics for therapeutic vectors to overcome various problems in existing viral and non-viral vector systems. Although the inefficient delivery of a large chromosome molecule into the cells remains to be overcome our 'trans-chromosomic' mice may provide a useful model system for in vivo assessment of the function and behavior of chromosome-based therapeutic vectors. As for the hChr14-derived hCF(SC20) minichromosome vector, we are in the process of minimizing it, so that it will no longer contain extra-human genes, aiming at using it as a vector for human gene therapy. For example, dystrophin is the largest gene (2.4 Mb) in humans and is responsible for Duchenne muscular dystrophy. 15 Because of its large size, the entire dystrophin locus has never been cloned even using YAC vectors. However, by using our HAC system, it will be able to be cloned and the HAC carrying the entire dystrophin locus could be evaluated for its usefulness as a therapeutic vector for Duchenne muscular dystrophy in a model animal, such as mdx mice. 16 
